Follow the people · Insider
Marc D. Beer
Marc D. Beer files insider transactions with the SEC as an executive chairman of biote (BTMD). We hold 2 disclosed purchases and sales filed since 9 March 2007, 2 of them in the last 90 days.
- Files forBTMD
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure12 August 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 26 May 2022 — 11 August 2026Executive Chairman · biote (BTMD)20 Form 4 lines · source: SEC Form 4
- Filed 30 June 2014 — 31 January 2018Director · Minerva Neurosciences (NERV)17 Form 4 lines · source: SEC Form 4
- Filed 27 October 2010 — 1 April 2015Chief Executive Officer · Aegerion Pharmaceuticals (AEGR)61 Form 4 lines · source: SEC Form 4
- Filed 7 March 2007 — 7 November 2007President & CEO · Viacell (VIAC)5 Form 4 lines · source: SEC Form 4
Everything they disclosed
103 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 115,950 shares of bioteSEC Form 412 August 2026Class A Common Stock · traded 10 August 2026 · filed 12 August 2026
- ▲ bought on the open market 16,000 shares of bioteSEC Form 412 August 2026Class A Common Stock · traded 11 August 2026 · filed 12 August 2026
- was granted 114,157 shares of biote (a derivative holding)SEC Form 410 June 2026Employee Stock Option (Right to Buy) · traded 8 June 2026 · filed 10 June 2026
- was granted 195,000 shares of biote (a derivative holding)SEC Form 413 May 2026Stock Option (Right to Buy) · traded 12 May 2026 · filed 13 May 2026
- was granted 495,600 shares of biote (a derivative holding)SEC Form 42 April 2025Employee Stock Option (Right to Buy) · traded 1 April 2025 · filed 2 April 2025
- ▲ bought on the open market 107,794 shares of bioteSEC Form 418 March 2025Class A Common Stock · traded 17 March 2025 · filed 18 March 2025
- was granted 543,958 shares of biote (a derivative holding)SEC Form 43 April 2024Employee Stock Option (Right to Buy) · traded 1 April 2024 · filed 3 April 2024
- was granted 317,163 shares of biote (a derivative holding)SEC Form 419 May 2023Stock Option (Right to Buy) · traded 17 May 2023 · filed 19 May 2023
- converted 865,384 shares of biote (a derivative holding)SEC Form 410 January 2023Retained Biote Units · traded 6 January 2023 · filed 10 January 2023
- converted 865,384 shares of bioteSEC Form 410 January 2023Class A Common Stock · traded 6 January 2023 · filed 10 January 2023
- acquired or disposed of, other 865,384 shares of bioteSEC Form 410 January 2023Class V Common Stock · traded 6 January 2023 · filed 10 January 2023
- ▼ sold on the open market 865,384 shares of bioteSEC Form 410 January 2023Class A Common Stock · traded 9 January 2023 · filed 10 January 2023
- was granted 477,721 shares of biote (a derivative holding)SEC Form 418 November 2022Stock Option (Right to Buy) · traded 15 November 2022 · filed 18 November 2022
- was granted 477,721 shares of biote (a derivative holding)SEC Form 416 November 2022Stock Option (Right to Buy) · traded 15 November 2022 · filed 16 November 2022
- acquired or disposed of, other 654,387 shares of biote (a derivative holding)SEC Form 419 September 2022Retained Biote Units · traded 26 May 2022 · filed 19 September 2022
- acquired or disposed of, other 654,387 shares of bioteSEC Form 419 September 2022Class V Common Stock · traded 26 May 2022 · filed 19 September 2022
- was granted 3,178,089 shares of biote (a derivative holding)SEC Form 431 May 2022Retained Biote Units · traded 26 May 2022 · filed 31 May 2022
- acquired or disposed of, other 654,387 shares of biote (a derivative holding)SEC Form 431 May 2022Retained Biote Units · traded 26 May 2022 · filed 31 May 2022
- was granted 3,178,089 shares of bioteSEC Form 431 May 2022Class V Common Stock · traded 26 May 2022 · filed 31 May 2022
- acquired or disposed of, other 654,387 shares of bioteSEC Form 431 May 2022Class V Common Stock · traded 26 May 2022 · filed 31 May 2022
- returned to the issuer 80,356 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 80,356 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- returned to the issuer 127,513 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 127,513 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- returned to the issuer 7,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 7,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- returned to the issuer 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- returned to the issuer 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 42 February 2018Stock Option (Right to Buy) · traded 31 January 2018 · filed 2 February 2018
- was granted 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 45 June 2017Stock Option (Right to Buy) · traded 1 June 2017 · filed 5 June 2017
- ▲ bought on the open market 25,000 shares of Minerva NeurosciencesSEC Form 421 March 2017Common Stock · traded 17 March 2017 · filed 21 March 2017
- ▲ bought on the open market 25,000 shares of Minerva NeurosciencesSEC Form 421 March 2017Common Stock · traded 20 March 2017 · filed 21 March 2017
- was granted 12,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 417 June 2016Stock Option (right to buy) · traded 16 June 2016 · filed 17 June 2016
- was granted 7,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 416 April 2015Stock Option (right to buy) · traded 2 February 2015 · filed 16 April 2015
- was granted 133,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 43 April 2015Stock Option (right to buy) · traded 1 April 2015 · filed 3 April 2015
- was granted 33,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 43 April 2015Restricted Stock Units · traded 1 April 2015 · filed 3 April 2015
- was granted 7,500 shares of Minerva Neurosciences (a derivative holding)SEC Form 44 February 2015Stock Option (right to buy) · traded 2 February 2015 · filed 4 February 2015
- was granted 120,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 45 January 2015Stock Option (right to buy) · traded 31 December 2014 · filed 5 January 2015
- gave away 769 shares of Aegerion PharmaceuticalsSEC Form 42 September 2014Common Stock · traded 28 August 2014 · filed 2 September 2014
- ▲ bought on the open market 7,700 shares of Aegerion PharmaceuticalsSEC Form 431 July 2014Common Stock · traded 31 July 2014 · filed 31 July 2014
- ▲ bought on the open market 2,300 shares of Aegerion PharmaceuticalsSEC Form 431 July 2014Common Stock · traded 31 July 2014 · filed 31 July 2014
- was granted 127,513 shares of Minerva Neurosciences (a derivative holding)SEC Form 49 July 2014Stock Option (Right to Buy) · traded 30 June 2014 · filed 9 July 2014
- ▲ bought on the open market 10,000 shares of Aegerion PharmaceuticalsSEC Form 44 June 2014Common Stock · traded 3 June 2014 · filed 4 June 2014
- ▲ bought on the open market 10,000 shares of Aegerion PharmaceuticalsSEC Form 427 May 2014Common Stock · traded 27 May 2014 · filed 27 May 2014
- exercised options over 6,400 shares of Aegerion PharmaceuticalsSEC Form 422 May 2014Common Stock · traded 21 May 2014 · filed 22 May 2014
- exercised options over 6,400 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 422 May 2014Stock Option (right to buy) · traded 21 May 2014 · filed 22 May 2014
- ▲ bought on the open market 10,000 shares of Aegerion PharmaceuticalsSEC Form 421 May 2014Common Stock · traded 20 May 2014 · filed 21 May 2014
- ▲ bought on the open market 30,000 shares of Aegerion PharmaceuticalsSEC Form 48 May 2014Common Stock · traded 8 May 2014 · filed 8 May 2014
- was granted 75,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 421 April 2014Stock Option (right to buy) · traded 1 April 2014 · filed 21 April 2014
- exercised options over 3,000 shares of Aegerion PharmaceuticalsSEC Form 427 March 2014Common Stock · traded 26 March 2014 · filed 27 March 2014
- exercised options over 3,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 427 March 2014Stock Option (right to buy) · traded 26 March 2014 · filed 27 March 2014
- exercised options over 4,380 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 46 December 2013Stock Option (right to buy) · traded 4 December 2013 · filed 6 December 2013
- exercised options over 4,380 shares of Aegerion PharmaceuticalsSEC Form 46 December 2013Common Stock · traded 4 December 2013 · filed 6 December 2013
- gave away 4,380 shares of Aegerion PharmaceuticalsSEC Form 46 December 2013Common Stock · traded 4 December 2013 · filed 6 December 2013
- exercised options over 39,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 46 November 2013Stock Option (right to buy) · traded 5 November 2013 · filed 6 November 2013
- exercised options over 39,000 shares of Aegerion PharmaceuticalsSEC Form 46 November 2013Common Stock · traded 5 November 2013 · filed 6 November 2013
- exercised options over 40,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 431 October 2013Stock Option (right to buy) · traded 30 October 2013 · filed 31 October 2013
- exercised options over 40,000 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 2,800 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 7,067 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 2,314 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 10,000 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 6,019 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 3,800 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 2,700 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 2,500 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 700 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 400 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 200 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 300 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- ▼ sold on the open market 1,200 shares of Aegerion PharmaceuticalsSEC Form 431 October 2013Common Stock · traded 30 October 2013 · filed 31 October 2013
- gave away 3,335 shares of Aegerion PharmaceuticalsSEC Form 46 September 2013Common Stock · traded 3 September 2013 · filed 6 September 2013
- exercised options over 60,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 416 August 2013Stock Option (right to buy) · traded 15 August 2013 · filed 16 August 2013
- exercised options over 60,000 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- ▼ sold on the open market 20,164 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- ▼ sold on the open market 12,301 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- ▼ sold on the open market 6,275 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- ▼ sold on the open market 21,160 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- ▼ sold on the open market 100 shares of Aegerion PharmaceuticalsSEC Form 416 August 2013Common Stock · traded 15 August 2013 · filed 16 August 2013
- was granted 105,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 43 April 2013Stock Option (right to buy) · traded 1 April 2013 · filed 3 April 2013
- ▲ bought on the open market 1,000 shares of Aegerion PharmaceuticalsSEC Form 430 March 2012Common Stock · traded 29 March 2012 · filed 30 March 2012
- ▲ bought on the open market 1,000 shares of Aegerion PharmaceuticalsSEC Form 423 March 2012Common Stock · traded 22 March 2012 · filed 23 March 2012
- was granted 85,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 49 February 2012Stock option (right to buy) · traded 1 February 2012 · filed 9 February 2012
- ▲ bought on the open market 5,270 shares of Aegerion PharmaceuticalsSEC Form 46 September 2011Common Stock · traded 1 September 2011 · filed 6 September 2011
- ▲ bought on the open market 1,484 shares of Aegerion PharmaceuticalsSEC Form 46 September 2011Common Stock · traded 1 September 2011 · filed 6 September 2011
- ▲ bought on the open market 8,265 shares of Aegerion PharmaceuticalsSEC Form 410 August 2011Common Stock · traded 9 August 2011 · filed 10 August 2011
- ▲ bought on the open market 1,800 shares of Aegerion PharmaceuticalsSEC Form 410 August 2011Common Stock · traded 9 August 2011 · filed 10 August 2011
- ▲ bought on the open market 4,938 shares of Aegerion PharmaceuticalsSEC Form 43 August 2011Common Stock · traded 1 August 2011 · filed 3 August 2011
- ▲ bought on the open market 1,392 shares of Aegerion PharmaceuticalsSEC Form 43 August 2011Common Stock · traded 1 August 2011 · filed 3 August 2011
- ▲ bought on the open market 64,516 shares of Aegerion PharmaceuticalsSEC Form 429 June 2011Common Stock · traded 29 June 2011 · filed 29 June 2011
- was granted 115,000 shares of Aegerion Pharmaceuticals (a derivative holding)SEC Form 43 June 2011Stock Option (right to buy) · traded 1 June 2011 · filed 3 June 2011
- ▲ bought on the open market 4,162 shares of Aegerion PharmaceuticalsSEC Form 43 June 2011Common Stock · traded 1 June 2011 · filed 3 June 2011
- ▲ bought on the open market 1,170 shares of Aegerion PharmaceuticalsSEC Form 43 June 2011Common Stock · traded 1 June 2011 · filed 3 June 2011
- ▲ bought on the open market 4,647 shares of Aegerion PharmaceuticalsSEC Form 45 April 2011Common Stock · traded 4 April 2011 · filed 5 April 2011
- ▲ bought on the open market 1,310 shares of Aegerion PharmaceuticalsSEC Form 45 April 2011Common Stock · traded 4 April 2011 · filed 5 April 2011
- ▲ bought on the open market 200 shares of Aegerion PharmaceuticalsSEC Form 417 December 2010Common Stock · traded 15 December 2010 · filed 17 December 2010
- ▲ bought on the open market 105,263 shares of Aegerion PharmaceuticalsSEC Form 427 October 2010Common Stock · traded 27 October 2010 · filed 27 October 2010
- exercised options over 600,000 shares of Viacell (a derivative holding)SEC Form 48 November 2007Stock option (right to buy) · traded 7 November 2007 · filed 8 November 2007
- exercised options over 100,000 shares of Viacell (a derivative holding)SEC Form 48 November 2007Stock option (right to buy) · traded 7 November 2007 · filed 8 November 2007
- exercised options over 600,000 shares of ViacellSEC Form 48 November 2007Common Stock · traded 7 November 2007 · filed 8 November 2007
- exercised options over 100,000 shares of ViacellSEC Form 48 November 2007Common Stock · traded 7 November 2007 · filed 8 November 2007
- was granted 100,000 shares of Viacell (a derivative holding)SEC Form 49 March 2007Stock Option (right-to-buy) · traded 7 March 2007 · filed 9 March 2007
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.